Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure
This trial is active, not recruiting.
|Sponsor||First Affiliated Hospital of Harbin Medical University|
|Start date||June 2014|
|End date||December 2015|
|Trial size||100 participants|
|Trial identifier||NCT02391142, CSB-CHF|
The purpose of this study is to evaluate the effect of Cardiac Sympathetic Blockade on Mortality, re-hospitalization rate, symptoms, quality of life, exercise tolerance, cardiac structure, systolic function, electrical activities and concentration of B - type natriuretic peptide precursor in patients with Chronic Heart Failure.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
lidocaine or ropivacaine epidural injection
All cause mortality
time frame: one year
time frame: one year
Male or female participants from 20 years up to 70 years old.
Inclusion Criteria: - 20-70 years old - more than 3 months of chronic heart failure history or clinical symptoms of heart failure last for more than 3 months (including acute episode of chronic heart failure), chronic heart failure diagnostic criteria refer to 2012ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - NYHA functional class III-IV, ejection fraction ≤45% - NT-proBNP>400ng/L Exclusion Criteria: - first episode of acute heart failure - unrepaired valvular heart disease accompanied with Hemodynamic changes - hypertrophic cardiomyopathy, pericardial disease, congenital heart disease, severe pulmonary hypertension - Second-degree type 2 or worse sinoatrial or atrioventricular block without pacemaker therapy - right heart failure caused by various diseases, respiratory failure or right heart failure induced by chronic obstructive pulmonary disease - overt renal decompensation: serum creatinine＞2.1mg/dl(186umol/L) - severe hepatic dysfunction, transaminase or alkaline phosphatase > 3 times the upper limit of normal - Cerebral vascular accident in three months( cerebral infarction, cerebral embolism, cerebral hemorrhage,etc) - life expectancy shorter than 6 months - patients with a previous or present history of tumour or precancerous lesions confirmed by pathological examination - Spine Deformity or skin infection at puncture site - participate in any clinical drug trials in the three months - the patients who do not sign the informed consent, unable or unwilling to comply with the requirements of the protocol or unsuitable for the study
|Official title||Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure|
Call for more information